Welcome to our dedicated page for Cumberland Pharmaceuticals news (Ticker: CPIX), a resource for investors and traders seeking the latest updates and insights on Cumberland Pharmaceuticals stock.
Cumberland Pharmaceuticals Inc. develops, acquires and commercializes branded prescription pharmaceutical products for hospital acute care, gastroenterology and oncology markets. Company news commonly covers operating results, product-portfolio updates and regulatory developments for FDA-approved brands such as Caldolor, Sancuso and Vaprisol.
Recurring updates also address Caldolor indication activity, Sancuso educational and commercial resources, and clinical or regulatory disclosures tied to Cumberland's ifetroban programs in systemic sclerosis, Duchenne muscular dystrophy-associated cardiomyopathy and idiopathic pulmonary fibrosis. Capital-structure items, material agreements and shareholder voting matters appear alongside the company's financial and portfolio updates.
Cumberland Pharmaceuticals (Nasdaq:CPIX) closed a strategic $100 million cash transaction with an Apotex subsidiary, transferring its branded U.S. pharmaceutical line after receiving over 99% shareholder approval. Cumberland retains its late-stage pipeline and majority interest in Cumberland Emerging Technologies.
The company will focus resources on developing ifetroban across multiple Phase 2 programs in Duchenne Muscular Dystrophy cardiomyopathy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis, and high-risk solid tumors, supported by FDA orphan, rare pediatric disease and Fast Track designations.
Cumberland Pharmaceuticals (NASDAQ:CPIX) presented updated Phase 2 FIGHT DMD ifetroban data for Duchenne cardiomyopathy at the 2026 Parent Project Muscular Dystrophy conference.
According to Cumberland, high‑dose ifetroban showed a 5.4% LVEF improvement, favorable 36‑month safety, and biomarker shifts suggesting reduced cardiac injury and enhanced tissue repair, with all completers entering open‑label extension.
RedHill Biopharma (NASDAQ:CPIX) closed a private placement of 8,571,429 ADSs (or equivalents) plus series A-1 and A-2 warrants at a combined $0.70 per ADS. The deal provides about $6 million gross upfront, with up to $13.4 million additional potential proceeds from warrant exercises.
According to RedHill, funds are expected to support near-term liquidity and a possible acquisition of commercial-stage, revenue-generating pharmaceutical assets, though no definitive agreement exists and there is no assurance any acquisition or warrant exercise will occur.
RedHill Biopharma (CPIX) entered a definitive agreement for a private placement of 8,571,429 ADSs (or equivalents) plus series A-1 and A-2 warrants at a combined price of $0.70 per ADS. Gross proceeds are expected to be about $6 million, with up to $13.4 million more if all warrants are exercised.
The deal is expected to close on June 22, 2026. According to RedHill, proceeds will fund a potential strategic product acquisition and support working capital, R&D and general corporate purposes.
RedHill Biopharma (ticker: CPIX) announced that the FDA granted rare pediatric disease designation to opaganib for treating neuroblastoma, in addition to existing orphan drug designation.
Benefits may include a Priority Review Voucher, potential seven years' marketing exclusivity, fee waivers, tax credits and accelerated review, if approved.
RedHill Biopharma (Nasdaq:CPIX) has begun recognition and enforcement proceedings in Korea for a New York Supreme Court final judgment against Kukbo totaling about $10.9 million.
The judgment, including roughly $8.9 million principal and $1.95 million legal fees with 9% interest, is final and no longer appealable.
Cumberland Pharmaceuticals (Nasdaq:CPIX)/b) and reported positive Phase 2a data for ifetroban in patients with high-risk solid tumors. The trial met its primary endpoint, showing safety and tolerability, and delivered encouraging secondary signals in distant metastatic recurrence and deaths due to metastatic disease, supporting further development.
RedHill Biopharma (NASDAQ:CPIX) is pursuing collaborations, including with the WHO SOLIDARITY CORE platform, to clinically evaluate opaganib as a potential Ebola virus disease (EVD) treatment, targeting the Bundibugyo ebolavirus subtype.
According to RedHill, opaganib has Phase 3 antiviral data in severe COVID-19 and preclinical Ebola activity, but remains investigational and unapproved.
Cumberland Pharmaceuticals (Nasdaq: CPIX) announced the launch of Vibativ (telavancin) injection in China through an exclusive commercialization partnership with SciClone Pharmaceuticals, following NMPA regulatory approval.
Vibativ is a once-daily, patented, FDA-approved antibiotic for serious Gram-positive infections, including MRSA-related hospital-acquired and ventilator-associated pneumonia and complicated skin and skin structure infections.
Cumberland Pharmaceuticals (Nasdaq: CPIX) reported Q1 2026 net revenues of $9.1 million and a net loss of $3.3 million. The company announced a $100 million strategic transaction to sell its FDA-approved branded U.S. portfolio to Apotex, while retaining development programs and majority ownership of Cumberland Emerging Technologies.
At March 31, 2026, total assets were $71.0 million, liabilities $49.7 million, and shareholders' equity $21.6 million. Ifetroban programs hold Fast Track, Orphan Drug, and Rare Pediatric Disease designations.